GHK-Cu

Discovery and Composition

GHK-Cu is a small tripeptide-copper complex consisting of the amino acid sequence glycyl-L-histidyl-L-lysine (GHK) bound to a copper(II) ion. It was first isolated in 1973 by biochemist Loren Pickart, who identified it in human plasma while investigating why older donor plasma appeared less effective at stimulating liver cell growth than plasma from younger donors. Pickart traced the difference to a decline in circulating GHK levels with age — from roughly 200 ng/mL in the third decade of life to around 80 ng/mL by the seventh.

The copper complex — not the naked GHK tripeptide — is the form most studied in skin and wound-healing research. Copper is tightly coordinated to the imidazole nitrogen of histidine, the α-amino group of glycine, and the peptide-bond nitrogen between glycine and histidine, producing a stable 1:1 chelate that delivers copper into cells at physiological concentrations.

Mechanism of Action

GHK-Cu is unusual among bioactive peptides in that it appears to influence hundreds of genes simultaneously. A 2010 analysis by Campbell and colleagues reported that GHK at 1 μM modulated the expression of roughly 4,000 human genes, predominantly resetting expression toward a younger phenotype. The pathways most reproducibly affected include:

• Extracellular matrix remodeling. Upregulation of collagen I and III, elastin, decorin, and glycosaminoglycan synthesis; modulation of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs).
• Anti-oxidant defense. Induction of SOD2, catalase, and glutathione-related enzymes; copper itself is a cofactor for several antioxidant enzymes.
• DNA repair. Upregulation of BRCA1 and other components of the homologous-recombination repair pathway.
• Angiogenesis. Stimulation of VEGF and capillary formation in wounded tissue.

The "anti-aging" framing often applied to GHK-Cu stems from this broad transcriptional reset effect combined with the observed decline of endogenous GHK with age.

Evidence Base

Unlike many peptides on this library, GHK-Cu has genuine human clinical data — most of it in cosmetic dermatology. Multiple placebo-controlled studies have shown topical GHK-Cu creams produce measurable improvements in skin thickness, elasticity, fine-line reduction, and photodamage repair over 12 weeks of twice-daily use. It has been a commercial skincare ingredient since the 1980s under names like Iamin and various trade-named "copper peptide" formulations.

Wound-healing research has documented accelerated closure of chronic wounds, diabetic ulcers, and post-surgical incisions in multiple small trials — a use case that actually preceded the cosmetic applications historically. A smaller but growing body of work examines systemic administration (subcutaneous injection) for hair regrowth and broader tissue repair, though the human evidence for systemic use is much thinner than for topical use.

Topical vs Injectable Use

The vast majority of the evidence base for GHK-Cu is topical. Skin-penetrating cream and serum formulations deliver the peptide locally at concentrations typically in the 0.05–3% range. Injectable protocols used in wellness settings are a more recent phenomenon and are not supported by equivalent clinical data. Anyone evaluating injectable GHK-Cu should be aware that the dose-response, bioavailability, and long-term safety profile of the injectable route remain poorly characterized relative to topical use.

For a structured comparison with the uncomplexed form, see our GHK reference page and the broader category overview for copper peptide complexes.

Safety and Regulatory Status

Topical GHK-Cu has a long and reassuring safety record — over four decades of cosmetic use with adverse events limited to occasional contact sensitivity. Injectable use is not FDA-approved for any indication and is available only through research-chemical suppliers or compounding pharmacies. Side effects reported anecdotally with subcutaneous injection are typically mild (injection-site reaction, transient skin flushing), but the absence of systematic safety data means long-term risk is unknown.

GHK-Cu is one of the better-supported peptides in this library for its topical indications and one of the more speculative for its injectable ones. For those interested in cosmetic peptide mechanisms more broadly, our GHK-Cu deep-dive article covers the research history and skincare landscape in more detail.